Document:

coll_Ex10_2

		
			Exhibit 10.2
		

		
			 
		

		
			AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT
		

		
			 
		

		
			THIS AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT (this “Amendment No. 2”) is entered into as of August 29, 2018, by and among Assertio Therapeutics, Inc. (f/k/a Depomed, Inc.), a Delaware corporation (“Assertio”), Collegium Pharmaceutical, Inc., a Virginia corporation (“Collegium”), and Collegium NF, LLC, a Delaware limited liability company and wholly owned subsidiary of Collegium (“Newco”) and amends that certain Commercialization Agreement, dated as of December 4, 2017, as amended January 9, 2018 (the “Commercialization Agreement”), by and among Assertio, Collegium, and Newco. Each of Assertio, Collegium and Newco is referred to herein individually as a “party” and collectively as the “parties.” Defined terms used herein but not otherwise defined herein shall have the meaning ascribed to such terms in the Commercialization Agreement.
		

		
			 
		

		
			WHEREAS, the parties entered into that certain Commercialization Agreement and wish to further amend certain terms of the Commercialization Agreement; and
		

		
			 
		

		
			WHEREAS, Section 17.4 of the Commercialization Agreement provides that the Commercialization Agreement may be amended by written agreement of the parties thereto.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants herein contained, the parties, intending to be legally bound, hereby agree as follows:
		

		
			 
		

		
			1.         Section 3.2(c)(viii) of the Commercialization Agreement is hereby amended and restated as follows:
		

		
			 
		

		
			“(viii)    To the extent permitted under the applicable CMO Supply Agreement, title to the Supplied Products ordered hereunder by or on behalf of Collegium shall transfer as follows:
		

		
			(A)        Title shall transfer from the applicable CMO to Depomed at such time as the Supplied Products are loaded onto a carrier vehicle arranged for and managed by Depomed for shipment at the shipping point; and
		

		
			(B)        Title shall transfer from Depomed to Collegium upon delivery of the Supplied Products to the loading dock of Collegium’s third-party logistics provider.
		

		
			Notwithstanding the terms set forth in subsection (B), above, in the event of a supply shortage with respect to the Supplied Products, Depomed and Collegium may modify the foregoing as the parties may mutually agree is necessary or advisable to facilitate the delivery and availability of such Supplied Products.
		

		
			The time during which Depomed retains title to the Supplied Products shall be referred to as the “Depomed Supplied Product Title Period.”  Collegium shall cover all costs incurred by, and insurance requirements of, Depomed during the Depomed Supplied Product Title Period pursuant to this Section 3.2(c)(viii) in accordance with the applicable provisions of Section 3.2(c).”
		

		
			 
		

		
			2.         Section 8.2 of the Commercialization Agreement is hereby amended and restated as follows:
		

		
			 
		

		
			Following the Closing, and in any event not later than October 31, 2018, Collegium shall obtain or reserve its own NDC Numbers for the Products and shall use commercially reasonable efforts to have in place as soon as reasonably practicable all
		

		
			
		

		
			

		 

		

			1

		

 

		

		
			 
		

		
			authorizations from Governmental Authorities necessary for Collegium to use such NDC Numbers for the Products.  Additionally, following the completion of the product serialization process, Assertio shall use its best efforts to complete the labelling changes required to reflect both the new NDC Numbers and the involvement of Collegium as soon as reasonably practical.  Following such time, Collegium shall use its new NDC numbers on all invoices, order and other communications with customers and Governmental Authorities.
		

		
			 
		

		
			3.         Except as herein expressly amended, the Commercialization Agreement is ratified and confirmed in all respects by each of the parties hereto and shall remain in full force and effect and enforceable against them in accordance with its terms. Unless the context otherwise requires, the term “Agreement” as used in the Commercialization Agreement shall be deemed to refer to the Commercialization Agreement as amended hereby.
		

		
			 
		

		
			4.         This Amendment No. 2 may be executed in one or more counterparts, each of which shall be deemed an original, and together shall constitute one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that the parties need not sign the same counterpart. This Amendment No. 2, following its execution, may be delivered via telecopier machine or other form of electronic delivery, which shall constitute delivery of an execution original for all purposes.
		

		
			 
		

		
			5.         This Amendment No. 2 shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law, principles or rules of such state, to the extent such principles or rules are not mandatorily applicable by statute and would permit or require the application of the laws of another jurisdiction.
		

		
			 
		

		
			(The remainder of this page is intentionally left blank. The signature page follows.)
		

		
			 
		

		
			 
		

		
			

		 

		

			2

		

 

		

		
			IN WITNESS WHEREOF, the parties have caused this Amendment No. 2 to be executed on the date first above written.
		

		
			 
		

		
			 
		

		
			 
		

			
					
						 

					
					
						ASSERTIO THERAPEUTICS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						COLLEGIUM PHARMACEUTICAL, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						COLLEGIUM NF, LLC

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Name:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Title:coll_Ex10_3

		
			Exhibit 10.3
		

		
			 
		

		
			SECOND AMENDMENT TO LEASE
		

		
			 
		

		
			THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made this 19th day of October, 2018, by and between Park at 95, LLC (“Landlord”) and Collegium Pharmaceutical, Inc. (“Tenant”).
		

		
			 
		

		
			R E C I T A L S:
		

		
			 
		

		
			A.          Reference is made to that certain Office Lease Agreement dated August 28, 2012 by and between 780 Dedham Street Holdings, LLC, the predecessor in title to Landlord, and Tenant, demising approximately 9,675 square feet of rentable square feet of space on the first floor of the building known as Suite 800, located at 780 Dedham Street, Canton, Massachusetts (the “Original Premises”). Said lease, as amended by that certain First Amendment to Lease dated March 24, 2015 (the “First Amendment”) is hereinafter referred to as the “Lease.”
		

		
			 
		

		
			B.          Landlord and Tenant are the current holders, respectively, of the landlord’s and tenant’s interests in the Lease.
		

		
			 
		

		
			C.          Pursuant to the First Amendment, Tenant increased its rentable square footage by adding to the Original Premises approximately 9,660 rentable square feet of space on the first floor of the Building known as Suite 700 (the “Additional Space”), for a total of 19,335 rentable square feet (the “Existing Space”).
		

		
			 
		

		
			D.          Tenant desires to reduce the Existing Space by surrendering to Landlord the Original Premises.
		

		
			 
		

		
			E.          Landlord and Tenant now desire to amend the Lease as set forth herein.
		

		
			 
		

		
			F.          Capitalized terms not defined herein shall have the meanings set forth in the Lease.
		

		
			 
		

		
			A G R E E M E N T S:
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree to amend the Lease as follows:
		

		
			 
		

		
			1.          Surrendered Space.  Effective as of the Delivery Date, Tenant’s rights and obligations under the Lease with respect to the Original Premises shall be, and hereby are, terminated. Tenant shall surrender to Landlord the Original Premises on or before October 31, 2018 (the “Delivery Date”). Effective as of the Delivery Date, and throughout the remaining Term of the Lease (as amended hereby), all references to the Premises in the Lease (as amended hereby) shall be deemed to mean the Additional Space, as identified on the plan attached hereto as Exhibit A (the “Remaining Space”). All of Tenant’s and Landlord’s rights and obligations under the Lease (as amended hereby) regarding the Remaining Space shall survive and continue to be in full force and effect.
		

		
			 
		

		
			2.          Surrendered Personal Property.  Tenant hereby agrees that any furniture remaining in the Original Premises on the day following the Delivery Date shall thereafter become the property of Landlord or, at Landlord’s option, the succeeding tenant, without any warranty by Tenant whatsoever, and Tenant’s rights, interest in, and ownership of said furniture shall thereupon be terminated.
		

		
			 
		

		
			 
		

		
			

		 

 

		

		
			3.          Termination Payment.  In consideration for Landlord’s execution and delivery of this Second Amendment and Landlord’s releasing Tenant from its future obligations under the Lease regarding the Original Premises, Tenant shall pay to Landlord the amount of $66,642.50 (the “Termination Payment”) together with Tenant’s execution and delivery of this Second Amendment.
		

		
			 
		

		
			4.          Tenant’s Pro Rata Share.  Effective on the Delivery Date, Tenant’s Pro Rata Share as set forth in Article I, Section E shall be 11.8%.
		

		
			5.          Base Rent.  Effective on the Delivery Date, Base Rent for the Remaining Space for the remaining Term of the Lease (as amended hereby) shall be as follows:
		

		
			 
		

			
					
						Period

					
					
						Annual Rent

					
					
						Monthly Rent

					
					
						Rent Per Square Foot

				
	
					
						10/31/18 – 8/31/19

					
					
						$119,397.60*

					
					
						$9,949.80

					
					
						$12.36*

				
	
					
						9/1/19 – 8/31/20

					
					
						$122,971.80

					
					
						$10,247.65

					
					
						$12.73

				

		
			*Annualized amount.
		

		
			 
		

		
			6.          Parking.  The first sentence of the first paragraph of Exhibit E, Section 3, Parking, is hereby deleted in its entirety and replaced with the following:
		

		
			 
		

		
			“Tenant shall have the right to use, on a non-reserved, non-exclusive basis, parking in the parking lot adjacent to the Building at a ratio of four (4) vehicle spaces per each one thousand (1,000) rentable square feet of the Premises (i.e. non-reserved parking for thirty-nine (39) motor vehicles based upon Tenant’s occupancy of 9,660 rentable square feet; the foregoing referred to herein as “Tenant's Parking Rights”).
		

		
			 
		

		
			7.          Brokers.  Landlord and Tenant each warrant and represent to the other that they have dealt with no brokers in connection with the negotiation or consummation of this Second Amendment other than CBRE, and in the event of any brokerage claim against either party by any person claiming to have dealt with either Landlord or Tenant in connection with this Second Amendment, the party with whom such person claims to have dealt shall defend and indemnify the other party against such claim.  Landlord shall be responsible for any commission due CBRE with respect to this Second Amendment per separate agreement.
		

		
			 
		

		
			8.          Ratification.  In all other respects the Lease shall remain unmodified and shall continue in full force and effect, as amended hereby.  The parties hereby ratify, confirm, and reaffirm all of the terms and conditions of the Lease, as amended hereby.  In the event of any conflict or inconsistency between this Second Amendment and the Lease, this Second Amendment shall control.
		

		
			 
		

		
			9.          Miscellaneous.  Each of Landlord and Tenant represents to the other that its signatory hereto has the authority to execute and deliver the same on its behalf.  This Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together will constitute one and the same instrument.  Images of the handwritten signature and acknowledgement (if any) pages of each signatory on this Second Amendment may be executed via an inked or “wet” signature and the executed pages may be delivered using portable document format (i.e., PDF) or similar file type and transmitted via electronic mail and, upon receipt, shall be deemed originals and binding upon the signatories hereto.
		

		
			 
		

		
			[Signatures appear on next page]
		

		
			
		

		
			

		 

		

			-  2  -

		

 

		

		
			IN WITNESS WHEREOF the parties hereto have executed this Second Amendment to Lease on the date first written above in multiple copies, each to be considered an original hereof, as a sealed instrument.
		

		
			 
		

			
					
						TENANT:

					
					
						    

					
					
						LANDLORD:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Collegium Pharmaceutical, Inc.,

					
					
						 

					
					
						Park at 95, LLC,

				
	
					
						a Virginia corporation

					
					
						 

					
					
						a Massachusetts limited liability company

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						 

					
					
						 

					
					
						By:

					
					
						 

				
	
					
						Name:

					
					
						 

					
					
						 

					
					
						Name:

					
					
						 

				
	
					
						Title:

					
					
						 

					
					
						 

					
					
						Title:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			-  3  -

		

 

		

		
			EXHIBIT A
		

		
			REMAINING SPACE PLAN
		

		
			 
		

		
			 
		

		 

		

			-  4  -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]